TECENTRIQ: payments to doctors
Payments that named TECENTRIQ as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $321.8M
- Providers
- 10,733
- Transactions
- 44,717
- Average per transaction
- $7,197
The per-transaction average — $7,197 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 10,733 providers the average total is $29,984, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech, Inc. | $313,751,925 | 97.5% |
| Genentech USA, Inc. | $6,107,910 | 1.9% |
| F. Hoffmann-la Roche AG | $1,637,799 | 0.5% |
| Chugai Pharmaceutical Co., Ltd. | $185,575 | 0.1% |
| Hoffmann-la Roche Limited | $71,253 | 0.0% |
| Roche Products Limited | $63,073 | 0.0% |